Retreatment regimen of rituximab monotherapy given at the relapse of severe HCV-related cryoglobulinemic vasculitis: Long-term follow up data of a randomized controlled multicentre study

•Rituximab retreatment at clinical relapse appears useful in the long term for severe cryoglobulinemic vasculitis.•Rituximab retreatment at clinical relapse is associated with a low incidence of severe hypogammaglobulinemia.•Rituximab retreatment at clinical relapse saves on the use of glucocorticoids in severe cases of cryoglobulinemic vasculitis.